Impact of Poor Tolerance and Discontinuation of the Dexamethasone during Treatment with Lenalidomide-Dexamethasone in Relapsed and Refractory Multiple MyelomaStéphanie Guidez, Xavier Leleu, Guillemette Fouquet et al.|Blood|2015Cited by 0
Time to Improve Bortezomib and Lenalidomide Lines of TherapyStéphanie Guidez, Hélène Demarquette, Denis Caillot et al.|University of Southern Denmark Research Portal (University of Southern Denmark)|2017Cited by 0
Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma (eNDMM) from ThalidomideHélène Demarquette, Xavier Leleu, Lionel Karlin et al.|Blood|2015Cited by 0
Impact of Poor Tolerance and Discontinuation of the Dexamethasone during Treatment with Lenalidomide-Dexamethasone in Relapsed and Refractory Multiple MyelomaStéphanie Guidez, Xavier Leleu, Guillemette Fouquet et al.|HAL (Le Centre pour la Communication Scientifique Directe)|2015Cited by 0